$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Safety and effectiveness of larotrectinib in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How much will a box of crizotinib cost after it is included in medical insurance in 2021?
2025-10-19 11:44:20
Check Details
Larotinib shows remarkable results in the treatment of NTRK mutation-positive lung cancer patients
2025-10-19 11:44:20
Check Details
Crizotinib has significant anti-cancer effect on ROS1-rearranged advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Nivolumab returns to the "battlefield" and joins forces with chemotherapy to help treat non-small cell lung cancer
2025-10-19 11:44:20
Check Details
FDA Grants Crizotinib Breakthrough Drug for ROS1-Rearranged Advanced Non-Small Cell Lung Cancer_Cornhule
2025-10-19 11:44:20
Check Details
A new first-line treatment option for ALK-positive non-small cell lung cancer-crizotinib
2025-10-19 11:44:20
Check Details
The emergence of larotrectinib gives lung cancer patients an additional choice
2025-10-19 11:44:20
Check Details
Can larotrectinib treat small cell lung cancer?
2025-10-19 11:44:20
Check Details
The effect of crizotinib in the treatment of ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How effective is the neoadjuvant drug nivolumab monotherapy in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Is the anti-cancer drug larotrectinib included in medical insurance? How much does a box cost?
2025-10-19 11:44:20
Check Details
1
2
...
3855
3856
3857
3858
3859
3860
3861
...
4152
4153
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer
2
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety
3
Almonertinib Safety Guide: Managing Adverse Reactions in NSCLC Treatment with a 3rd-Gen EGFR TKI
4
Pimitespib Storage Guidelines: Temperature, Humidity & Light Control for Home Use
5
Cemiplimab (Libtayo) Drug Information
6
Mirvetuximab Soravtansine (Elahere): FRα-Targeted ADC for Platinum-Resistant Ovarian Cancer
7
The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update
8
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
9
A Revolutionary Targeted Therapy for Hematological Malignancies
10
A New Option for Advanced Renal Cell Carcinoma Treatment
11
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
12
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description: